en.Wedoany.com Reported - cliexa and OpiSafe recently announced a strategic partnership to launch a next-generation behavioral health medication management platform designed for health systems, payers, government agencies, and healthcare provider organizations. cliexa is an artificial intelligence-powered clinical intelligence company, while OpiSafe is a leader in opioid prescribing, monitoring, and management technology.
The solution resulting from this partnership is designed to identify risks, support evidence-based interventions, and improve access to behavioral health and addiction treatment services. It integrates predictive analytics, clinical decision support, patient engagement, and care coordination technologies that work synergistically within existing healthcare workflows, reflecting the industry's shift toward interoperable clinical intelligence ecosystems.
Addressing challenges such as opioid misuse, chronic pain management, regulatory compliance, and behavioral health access, the joint platform provides clinicians with actionable intelligence and guided workflows directly within existing electronic health record systems.
The collaboration integrates three core capabilities: AI-driven opioid use disorder risk prediction, which identifies high-risk patients through advanced predictive analytics and real-time clinical intelligence, including a four-level risk stratification and explainable risk factors; patented opioid tapering management, putting evidence-based tapering protocols and monitoring workflows into practice; and patented treatment referral and care coordination, streamlining closed-loop referrals to behavioral health, addiction treatment, and specialty care services. Together, these capabilities support the entire process from risk identification to intervention, treatment coordination, and long-term management.
Mehmet Kazgan, Founder and CEO of cliexa, stated that the opioid crisis remains one of the most complex and costly challenges in healthcare, and providers often lack a connected pathway from risk identification to intervention. This partnership offers a unified platform that helps clinicians identify risks earlier, guide safer prescribing decisions, and connect patients with appropriate treatment before adverse outcomes occur.
Dr. Robert J. Valuck, CEO of RxAssurance (operating as OpiSafe), noted that healthcare organizations increasingly need connected clinical intelligence platforms. Combining predictive analytics with clinical decision support, tapering management, referral coordination, and patient engagement technologies expands the capabilities of the OpiSafe platform, supporting a more proactive, data-driven approach to opioid and behavioral health management.
The joint platform is protected by multiple issued and pending patents covering opioid tapering and treatment referral technologies, forming a differentiated solution that connects predictive intelligence, intervention management, and coordinated treatment pathways. Healthcare organizations can use it to identify high-risk patients before conditions worsen, support evidence-based management initiatives, automate clinical workflows, improve compliance, facilitate safe tapering and discontinuation plans, and increase access to behavioral health and addiction treatment services through closed-loop referral management.
cliexa is an AI-driven clinical intelligence platform that leverages the cliexaAI closed-loop clinical intelligence framework to transform fragmented clinical, claims, and patient-generated data into actionable insights. Its opioid use disorder risk prediction solution, validated by Mayo Clinic Platform, helps healthcare organizations identify high-risk patients earlier and implement proactive interventions.
OpiSafe provides safe, guideline-compliant technology solutions for opioid prescribing, opioid management, chronic pain management, and behavioral health coordination. Its patented technology helps healthcare providers, health systems, and payers standardize opioid management programs, improve patient safety, reduce risk, and promote evidence-based treatment pathways.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
